Interstitial Lung Disease with CC DRG Reimbursement Guide

DRG 197 pertains to inpatient admissions for interstitial lung disease with at least one Complication or Comorbidity, encompassing conditions like pulmonary fibrosis and sarcoidosis that require inpatient care. This Diagnosis-Related Group matters for inpatient reimbursement because Complication or Comorbidity status affects relative payment weights and resource allocation under Medicare.

DRG 197 Overview

DRG 197 covers inpatient admissions for interstitial lung disease when a patient has at least one Complication or Comorbidity. This Diagnosis-Related Group captures cases where pulmonary fibrosis, hypersensitivity pneumonitis, sarcoidosis, or other diffuse parenchymal lung disorders require inpatient management and additional resources due to concomitant conditions. It matters for Medicare payment because the presence of a Complication or Comorbidity influences relative payment weights and resource intensity compared with non-Complication or Comorbidity cases. Accurate clinical and coding documentation determines assignment to this Diagnosis-Related Group and thus affects reimbursement.

Acute inpatient management and ventilatory-support trials: studies in this area evaluate strategies for respiratory support (e.g., high-flow nasal oxygen, noninvasive ventilation protocols, or optimized mechanical ventilation strategies) and adjunctive interventions during hospital admission for patients with acute exacerbations of interstitial lung disease (ILD). The patient population typically includes adults hospitalized with acute respiratory failure or severe hypoxemia secondary to ILD exacerbation, often with cardiopulmonary comorbidities that qualify them for DRG 197. This research is relevant to providers and payers because optimizing in-hospital respiratory management can reduce length of stay, ICU transfers, and short-term mortality, directly affecting resource use and reimbursement under inpatient DRG-based payment systems.
Comparative effectiveness and pharmacologic-modifier studies for disease progression: trials and observational comparative-effectiveness research assess anti-fibrotic agents, immunomodulatory regimens, or combinations versus usual care in patients with progressive fibrosing ILD phenotypes who are admitted with complications or worsening symptoms. These studies enroll patients with different ILD subtypes (idiopathic pulmonary fibrosis and other fibrosing ILDs) to determine which medication strategies reduce readmissions, slow functional decline, or prevent future exacerbations. Findings inform treatment pathways that can lower rehospitalization rates and downstream costs, guiding payer coverage decisions and clinicians’ discharge planning for high-risk DRG 197 patients.
Post-discharge outcomes, rehabilitation, and palliative-care integration studies: research in this domain evaluates transitional care interventions, pulmonary rehabilitation, home oxygen strategies, or early palliative-care models aimed at patients recently discharged after an ILD-related hospitalization. The population includes survivors of ILD exacerbation with persistent hypoxemia, reduced 6-minute walk distance, or high symptom burden; studies measure readmission rates, quality of life, symptom control, and use of healthcare resources over months. This area is important to providers and payers because effective post-discharge programs can decrease costly readmissions, improve patient-centered outcomes, and influence bundled-payment or value-based care metrics linked to DRG 197 admissions.

Acute inpatient management and ventilatory-support trials: studies in this area evaluate strategies for respiratory support (e.g., high-flow nasal oxygen, noninvasive ventilation protocols, or optimized mechanical ventilation strategies) and adjunctive interventions during hospital admission for patients with acute exacerbations of interstitial lung disease (ILD). The patient population typically includes adults hospitalized with acute respiratory failure or severe hypoxemia secondary to ILD exacerbation, often with cardiopulmonary comorbidities that qualify them for DRG 197. This research is relevant to providers and payers because optimizing in-hospital respiratory management can reduce length of stay, ICU transfers, and short-term mortality, directly affecting resource use and reimbursement under inpatient DRG-based payment systems.
Comparative effectiveness and pharmacologic-modifier studies for disease progression: trials and observational comparative-effectiveness research assess anti-fibrotic agents, immunomodulatory regimens, or combinations versus usual care in patients with progressive fibrosing ILD phenotypes who are admitted with complications or worsening symptoms. These studies enroll patients with different ILD subtypes (idiopathic pulmonary fibrosis and other fibrosing ILDs) to determine which medication strategies reduce readmissions, slow functional decline, or prevent future exacerbations. Findings inform treatment pathways that can lower rehospitalization rates and downstream costs, guiding payer coverage decisions and clinicians’ discharge planning for high-risk DRG 197 patients.
Post-discharge outcomes, rehabilitation, and palliative-care integration studies: research in this domain evaluates transitional care interventions, pulmonary rehabilitation, home oxygen strategies, or early palliative-care models aimed at patients recently discharged after an ILD-related hospitalization. The population includes survivors of ILD exacerbation with persistent hypoxemia, reduced 6-minute walk distance, or high symptom burden; studies measure readmission rates, quality of life, symptom control, and use of healthcare resources over months. This area is important to providers and payers because effective post-discharge programs can decrease costly readmissions, improve patient-centered outcomes, and influence bundled-payment or value-based care metrics linked to DRG 197 admissions.

OpenPayer

Summary & Overview

Interstitial Lung Disease with CC: Inpatient Reimbursement Overview

DRG 197 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes